About the Phase 3 KINECT®-DCP Study The Phase 3, randomized, double-blind, placebo-controlled study was designed to evaluate the efficacy, safety and tolerability of valbenazine for the treatment of ...
SAN DIEGO, Dec. 22, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 3 KINECT®-DCP study evaluating the efficacy, safety, and tolerability of valbenazine ...
SAN DIEGO, Dec. 22, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 3 KINECT ®-DCP study evaluating the efficacy, safety, and tolerability of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback